Clik here to view.
The Medicines Company Collaborates with AstraZeneca To Sell Brilinta...
The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca’s struggling oral antiplatelet drug. The collaboration is the first stage of ”a global...
View ArticleClik here to view.
UK Politician Urges More Use Of Ticagrelor To Preserve AstraZeneca Jobs In UK
Use it or lose it. A UK politician is urging the National Health Service (NHS) to increase use of the antiplatelet drug ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) in...
View ArticleClik here to view.
Top Line Results: No Cardiovascular Benefits Found For Saxagliptin
Top line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and...
View ArticleClik here to view.
Pretreatment with Prasugrel Not Indicated in NSTEMI
Although current guidelines strongly recommend that dual antiplatelet therapy be administered early in treating patients with non-ST-segment-elevation acute myocardial infarction (NSTEMI), it is...
View ArticleClik here to view.
Cardiovascular Outcome Studies in Diabetes Drugs Finally Arrive
For many years critics have bemoaned the absence of outcome studies for the many diabetes drugs used to lower blood glucose levels. Now, finally, two large trials with different drugs have been...
View ArticleClik here to view.
US Department Of Justice Ends Investigation Of AstraZenca Trial
AstraZeneca announced today that the US Department of Justice has ended its investigation into alleged misconduct associated with the pivotal PLATO trial. The company said it had fully cooperated with...
View ArticleClik here to view.
AstraZeneca Drug Improves Outcomes After Heart Attacks
For the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. Because it has...
View ArticleClik here to view.
AstraZeneca Drug ‘Approaching The Point Of Diminishing Returns’
After a heart attack (myocardial infarction or MI) patients remain at high risk for recurrent events. The precise role of blood thinning with dual antiplatelet therapy to lower this risk has been the...
View ArticleNo, $75 Million Won’t Cure Heart Disease Or Reinvent Science
–Silicon Valley hype and hubris come to cardiology. We may be close to peak hype and hubris in cardiology. This week some of the smartest people on the planet said that $75 million can help find new...
View Article
